吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Nov 10 2016

Full Issue

Months Of Negotiations Over 'Cures' Bill Could Unravel In Light Of Trump Presidency

The package would have simplified the regulatory process of prescription drugs and medical devices and provided funding for health care innovation projects. However, its future is now uncertain.

Lawmakers have spent months negotiating a package of bills that would clear the path for a major shift in the way the country regulates prescription drugs and medical devices聽鈥 one meant to help spur innovation in health care. In exchange for simplifying the regulatory process, a top priority for Republicans, Democrats would secure additional funding for the Food and Drug Administration and the National Institutes of Health. (Kaplan, 11/10)

Donald Trump will be the nation鈥檚 next president, the shocking conclusion to a long and divisive campaign in which science was barely mentioned. Now, many people in the research community聽are contemplating what a Trump administration will mean for their work 鈥 and they don't like the outlook. 鈥淭rump will be the first anti-science president we have ever had,鈥 Michael Lubell, director of public affairs for the American Physical Society, told Nature聽on Wednesday. 鈥淭he consequences are going to be very, very severe.鈥 (Kaplan, 11/9)

Meanwhile, a look at how the election affected key health care committees聽鈥

President-elect Donald Trump opens a door for Republicans to follow through on a longtime vow to repeal Obamacare. But it鈥檚 unclear exactly how Republicans would replace the law, and which GOP lawmakers might lead the key committees in the House to work on that effort. That鈥檚 because Rep. Fred Upton (R-Mich.) is term-limited, so he will step down as Energy and Commerce Committee Chairman. Reps. Greg Walden (R-Ore.), John Shimkus (R-Ill.) and former chairman Joe Barton (R-Texas) are all vying for the chairmanship. Shimkus currently sits on the health subcommittee. Walden chairs the communications subcommittee. Walden may be the favorite because he just handed the Republicans a better-than-expected win. (McIntire, 11/9)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, July 31
  • Thursday, July 30
  • Wednesday, July 29
  • Tuesday, July 28
  • Monday, July 27
  • Friday, July 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF